G1 Therapeutics Inc represents values of innovation, dedication, and patient-centered care. Their corporate philosophy revolves around the development of novel therapies to address the unmet needs of patients with cancer. As a biopharmaceutical company, G1 Therapeutics is committed to improving outcomes and quality of life for individuals battling cancer. Their focus on precision medicine and understanding the biology of cancer has led to the creation of potential breakthrough therapies. G1 Therapeutics Inc strives to make a positive impact in the lives of patients worldwide by relentlessly pursuing innovative approaches to cancer treatment.

G1 Therapeutics Inc is primarily present in the United States.

G1 Therapeutics Inc, a renowned biopharmaceutical company, has achieved several significant milestones. One notable accomplishment is the FDA approval of their key drug, trilaciclib, as a treatment for small cell lung cancer (SCLC). Additionally, G1 Therapeutics Inc successfully completed a Phase 2 clinical trial demonstrating positive results for trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). The company also entered into partnerships with leading organizations, such as Boehringer Ingelheim, for the global development and commercialization of their investigational oral selective estrogen receptor degrader (SERD) in breast cancer. These achievements solidify G1 Therapeutics Inc as a promising player in the field of oncology therapeutics.

G1 Therapeutics Inc is a pharmaceutical company specializing in the development of novel therapies for patients with cancer. Founded in 2008, G1 Therapeutics is focused on advancing their pipeline of small molecule therapies that target key pathways involved in cell cycle progression and DNA damage repair. The company has garnered attention for its innovative approach to cancer treatment, utilizing precision medicine and targeted therapies. G1 Therapeutics' dedication to improving the lives of cancer patients has propelled its growth and success in the biopharmaceutical industry. With a strong focus on clinical development and strategic partnerships, G1 Therapeutics continues to pave the way for advancements in oncology therapeutics.

The main competitors of G1 Therapeutics Inc in the market include pharmaceutical companies such as Bristol-Myers Squibb, Merck & Co., and Pfizer Inc.

G1 Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of G1 Therapeutics Inc focuses on the development and commercialization of novel therapies for the treatment of cancer. The company aims to address the unmet needs of patients by advancing its pipeline of potential therapies that target specific cellular pathways involved in tumor growth. G1 Therapeutics Inc leverages its expertise in cell cycle biology and deep understanding of cancer biology to develop innovative drugs, with a particular focus on targeting metastatic breast cancer and small cell lung cancer. Through strategic partnerships and collaborations, G1 Therapeutics Inc aims to bring its potential breakthrough therapies to market, improving the lives of cancer patients worldwide.

G1 Therapeutics hissesinin F/K oranı -16,66.

G1 Therapeutics KUV 4,93 dir.

G1 Therapeutics için AlleAktien Kalite Skoru 2/10'dur.

beklenen G1 Therapeutics cirosu 75,01 Milyon. USD dir.

beklenen G1 Therapeutics karı -22,20 Milyon. USD olarak gerçekleşmiştir.

G1 Therapeutics is a biopharmaceutical company specializing in the development of groundbreaking cancer drugs to improve the lives of patients suffering from various forms of cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics' business model is based on the development and marketing of drugs targeting specific target proteins found in cancer cells. By targeting these proteins, the company effectively inhibits the proliferation and spread of cancer cells. In addition, the company also provides services in the areas of research and development and clinical trials to ensure that the effectiveness and safety of its drugs are of the highest level. The company has developed several product lines targeting different types of cancer. Primarily, this includes innovative therapeutics for the treatment of advanced stage cancers, particularly advanced lung cancer and breast cancer. The company's flagship product is Rintodestrant (G1T48), an orally administered selective estrogen receptor modulator (SERM) currently being investigated in phase 2b clinical trials for the treatment of ER-positive (ER+) breast cancer. Rintodestrant offers an alternative treatment profile for patients receiving anti-hormone therapies, improving their quality of life by minimizing undesirable effects such as hot flashes, bleeding, and cardiovascular diseases. The company has also developed a drug candidate called Trilaciclib (G1T28), which is used as the first and only myelosuppression-reducing drug to protect bone marrow associated with chemotherapy. Trilaciclib should be used in situations where significant myelosuppressive chemotherapy is anticipated. Alongside chemotherapy, it may help reduce the toxic effects on bone marrow function, especially hematopoietic stem cells. With the introduction of additional monoclonal antibodies and immunotherapy variants, the company aims to expand its presence in the field of cancer treatment and expand its portfolio of drugs manufactured on an improved medical basis. In addition to its own product development, G1 Therapeutics works closely with partners in the science and industry sectors to expand its knowledge and capabilities in the field of cancer research and development. Overall, G1 Therapeutics pursues an innovative business model and positions itself as a key partner in cancer research and development. Through the constant development of new drugs and services, the company contributes to improving healthcare and ensuring that patients can be effectively treated against cancer.

G1 Therapeutics, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

G1 Therapeutics için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

G1 Therapeutics şirketinin ISIN kodu US3621LQ1099’dir.

G1 Therapeutics 'nin WKN'si A2DR0J 'dir.

G1 Therapeutics için Ticker GTHX’dir.

Son 12 ay içerisinde G1 Therapeutics, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için G1 Therapeutics, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

G1 Therapeutics şirketinin mevcut temettü verimi .

G1 Therapeutics dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

G1 Therapeutics, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

G1 Therapeutics, 'Sağlık' sektörüne atanmıştır.

Son G1 Therapeutics tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 20.09.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 20.09.2024 olarak gerçekleşti.

2023 yılında G1 Therapeutics tarafından 0 USD olarak temettüler dağıtıldı.

G1 Therapeutics hisselerinin temettüleri USD olarak dağıtılır.